SHCBP1L

Summary

SHCBP1L (SHC binding and spindle associated 1 like, HGNC:16788) is a protein-coding gene on chromosome 1q25.3, encoding Testicular spindle-associated protein SHCBP1L (Q9BZQ2). Testis-specific spindle-associated factor that plays a role in spermatogenesis.

This gene encodes a Src homology 2 domain-binding protein 1-like protein. The encoded protein interacts with heat shock 70 kDa protein 2 and may be involved in maintaining spindle integrity during meiosis. This gene is located in region of chromoso0me 1 encompassing a prostate cancer susceptibility locus.

Source: NCBI Gene 81626 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 120 total
• MANE Select transcript: NM_030933

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16788
Approved symbol	SHCBP1L
Name	SHC binding and spindle associated 1 like
Location	1q25.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000157060
Ensembl biotype	protein_coding
OMIM	619514
Entrez	81626

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 4 protein_coding_CDS_not_defined, 1 protein_coding

ENST00000367547, ENST00000467208, ENST00000483655, ENST00000488956, ENST00000497549

RefSeq mRNA: 2 — MANE Select: NM_030933 NM_001345928, NM_030933

CCDS: CCDS30955

Canonical transcript exons

ENST00000367547 — 10 exons

Exon	Start	End
ENSE00001900619	182952729	182953166
ENSE00003484713	182903039	182903161
ENSE00003550352	182904180	182904430
ENSE00003562230	182939467	182939553
ENSE00003605306	182929647	182929752
ENSE00003633223	182899865	182900234
ENSE00003664512	182951318	182951467
ENSE00003678002	182940329	182940543
ENSE00003687127	182939176	182939394
ENSE00003687583	182905496	182905649

Expression profiles

Bgee: expression breadth broad, 53 present calls, max score 97.27.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.3880 / max 323.4279, expressed in 17 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
16172	0.3880	17

Top tissues by expression

221 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	97.27	gold quality
right testis	UBERON:0004534	97.25	gold quality
left testis	UBERON:0004533	97.23	gold quality
male germ cell	CL:0000015	96.47	gold quality
testis	UBERON:0000473	94.04	gold quality
adult organism	UBERON:0007023	91.32	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.64	gold quality
diaphragm	UBERON:0001103	75.20	gold quality
olfactory bulb	UBERON:0002264	70.74	gold quality
type B pancreatic cell	CL:0000169	69.81	gold quality
triceps brachii	UBERON:0001509	64.05	gold quality
cervix squamous epithelium	UBERON:0006922	63.91	gold quality
tongue squamous epithelium	UBERON:0006919	61.68	gold quality
gluteal muscle	UBERON:0002000	61.65	gold quality
nephron tubule	UBERON:0001231	60.36	gold quality
cervix epithelium	UBERON:0004801	59.93	gold quality
CA1 field of hippocampus	UBERON:0003881	59.70	gold quality
orbitofrontal cortex	UBERON:0004167	59.59	gold quality
pancreatic ductal cell	CL:0002079	59.30	silver quality
mucosa of urinary bladder	UBERON:0001259	58.36	gold quality
thymus	UBERON:0002370	57.44	gold quality
quadriceps femoris	UBERON:0001377	56.76	gold quality
nasal cavity epithelium	UBERON:0005384	56.68	gold quality
vastus lateralis	UBERON:0001379	55.54	gold quality
deltoid	UBERON:0001476	55.54	gold quality
metanephric glomerulus	UBERON:0004736	54.81	gold quality
vena cava	UBERON:0004087	54.55	gold quality
lower lobe of lung	UBERON:0008949	54.47	silver quality
oviduct epithelium	UBERON:0004804	54.39	gold quality
cerebellar vermis	UBERON:0004720	54.19	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-GEOD-124263	yes	946.10
E-GEOD-134144	yes	770.29
E-ANND-3	no	4.07

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

14 targeting SHCBP1L, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-6516-3P	99.65	68.57	1238
HSA-MIR-4452	99.50	68.45	1493
HSA-MIR-302B-5P	99.50	69.49	1857
HSA-MIR-302D-5P	99.50	69.34	1863
HSA-MIR-183-3P	99.41	69.41	1598
HSA-MIR-758-3P	98.42	68.60	1122
HSA-MIR-96-3P	97.47	68.03	839
HSA-MIR-194-3P	97.36	65.96	1027
HSA-MIR-6742-5P	96.32	64.01	869

Literature-anchored findings (GeneRIF, showing 1)

• SHCBP1L is a conserved mammalian protein predominantly expressed in male germ cells and it maintains spindle stability during meiosis in testis. (PMID:24557841)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Shcbp1l	ENSMUSG00000042708
rattus_norvegicus	Shcbp1l	ENSRNOG00000002691

Paralogs (1): SHCBP1 (ENSG00000171241)

Protein

Protein identifiers

Testicular spindle-associated protein SHCBP1L — Q9BZQ2 (reviewed: Q9BZQ2)

Alternative names: SHC SH2 domain-binding protein 1-like protein

All UniProt accessions (1): Q9BZQ2

UniProt curated annotations — full annotation on UniProt →

Function. Testis-specific spindle-associated factor that plays a role in spermatogenesis. In association with HSPA2, participates in the maintenance of spindle integrity during meiosis in male germ cells.

Subunit / interactions. Interacts with HSPA2; this interaction may promote the recruitment of HSPA2 to the spindle.

Subcellular location. Cytoplasm. Cytoskeleton. Spindle.

Tissue specificity. Expressed in spermatocytes and elongating spermatids inside the seminiferous tubules (at protein level). Testis-specific.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9BZQ2-3	3	yes
Q9BZQ2-2	2
Q9BZQ2-4	4

RefSeq proteins (2): NP_001332857, NP_112195* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006626	PbH1	Repeat
IPR006633	Carb-bd_sugar_hydrolysis-dom	Domain
IPR011050	Pectin_lyase_fold/virulence	Homologous_superfamily
IPR012334	Pectin_lyas_fold	Homologous_superfamily
IPR039448	Beta_helix	Domain
IPR045140	SHCBP1-like	Family
IPR057508	SHCBP-like_N	Domain

Pfam: PF13229, PF23762

UniProt features (20 total): repeat 4, modified residue 4, splice variant 4, sequence conflict 2, compositionally biased region 2, chain 1, sequence variant 1, region of interest 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BZQ2-F1	77.61	0.47

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 53, 570, 645, 8

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 72 (showing top): GOBP_CHROMOSOME_ORGANIZATION, MYOGENIN_Q6, GOBP_MALE_GAMETE_GENERATION, GOBP_POSITIVE_REGULATION_OF_ORGANELLE_ORGANIZATION, AAAYRNCTG_UNKNOWN, GOBP_ORGANELLE_FISSION, MYOD_01, GOBP_CYTOKINESIS, GRE_C, MYOD_Q6, IK2_01, GOBP_POSITIVE_REGULATION_OF_CHROMOSOME_ORGANIZATION, GOBP_DEVELOPMENTAL_PROCESS_INVOLVED_IN_REPRODUCTION, GOBP_MEIOTIC_CELL_CYCLE_PROCESS, GOBP_REGULATION_OF_CHROMOSOME_ORGANIZATION

GO Biological Process (4): male meiosis cytokinesis (GO:0007112), spermatogenesis (GO:0007283), cell differentiation (GO:0030154), positive regulation of chromosome organization (GO:2001252)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (4): meiotic spindle (GO:0072687), cytoplasm (GO:0005737), spindle (GO:0005819), cytoskeleton (GO:0005856)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular membraneless organelle	2
male meiotic nuclear division	1
meiotic cytokinesis	1
developmental process involved in reproduction	1
male gamete generation	1
cellular developmental process	1
positive regulation of organelle organization	1
regulation of chromosome organization	1
chromosome organization	1
binding	1
spindle	1
intracellular anatomical structure	1
cellular anatomical structure	1
microtubule cytoskeleton	1

Protein interactions and networks

STRING

766 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SHCBP1L	CABS1	Q96KC9	644
SHCBP1L	SPATA3	Q8NHX4	534
SHCBP1L	HSPA2	P54652	496
SHCBP1L	TMCO5A	Q8N6Q1	486
SHCBP1L	PDCL2	Q8N4E4	476
SHCBP1L	TMCO2	Q7Z6W1	467
SHCBP1L	CCDC187	A0A096LP49	456
SHCBP1L	FBXO47	Q5MNV8	456
SHCBP1L	CCDC54	Q8NEL0	446
SHCBP1L	CXorf65	A6NEN9	445
SHCBP1L	METTL24	Q5JXM2	442
SHCBP1L	FAM209A	Q5JX71	437
SHCBP1L	C20orf173	Q96LM9	434
SHCBP1L	SMIM23	A6NLE4	425
SHCBP1L	ZC3H11D	Q8NA57	418
SHCBP1L	RNF151	Q2KHN1	418

IntAct

21 interactions, top by confidence:

A	B	Type	Score
SHCBP1L	ZNF835	psi-mi:“MI:0915”(physical association)	0.560
CASP6	SHCBP1L	psi-mi:“MI:0915”(physical association)	0.560
SHCBP1L	HIP1	psi-mi:“MI:0915”(physical association)	0.560
LAMP2	SHCBP1L	psi-mi:“MI:0915”(physical association)	0.560
SH3GLB1	SHCBP1L	psi-mi:“MI:0915”(physical association)	0.560
PRPF40A	SHCBP1L	psi-mi:“MI:0915”(physical association)	0.560
SHCBP1L	H1-1	psi-mi:“MI:0915”(physical association)	0.400
BRAP	SHCBP1L	psi-mi:“MI:0915”(physical association)	0.370
SHCBP1L	ZNF835	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (7): SHCBP1L (Synthetic Lethality), SHCBP1L (Two-hybrid), SHCBP1L (Two-hybrid), SHCBP1L (Proximity Label-MS), SHCBP1L (Affinity Capture-MS), SHCBP1L (Cross-Linking-MS (XL-MS)), UBC (Cross-Linking-MS (XL-MS))

ESM2 similar proteins: A0A1B0GUJ8, A1A5R7, A2CJ06, A7E3N2, B1H224, B8QB46, D3Z8Y2, D3ZSP7, O55036, P0CG32, P54274, P70371, Q14BQ3, Q29RJ0, Q2HJ46, Q2T9U5, Q3TTP0, Q4R8X0, Q4R9F7, Q4VA55, Q5DTT8, Q5RBH9, Q5TKR9, Q5U310, Q5ZIX8, Q6DJS0, Q6ZQF7, Q71M44, Q7Z2W4, Q7Z7J5, Q80VH0, Q80VM8, Q8BMD7, Q8BZ21, Q8CCG4, Q8CDN1, Q8JZW8, Q8ND61, Q8TE76, Q8VD24

Diamond homologs: Q3TTP0, Q640F2, Q8NEM2, Q9BZQ2, Q9Z179, Q6GPE9

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

120 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	110
Likely benign	6
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1967 predictions. Top by Δscore:

Variant	Effect	Δscore
1:182903160:CC:C	acceptor_gain	1.0000
1:182903160:CCCT:C	acceptor_loss	1.0000
1:182903161:CC:C	acceptor_gain	1.0000
1:182903162:CTGT:C	acceptor_loss	1.0000
1:182903163:T:A	acceptor_loss	1.0000
1:182905494:AC:A	donor_gain	1.0000
1:182905495:CC:C	donor_gain	1.0000
1:182939192:C:A	donor_gain	1.0000
1:182939458:TATAC:T	donor_loss	1.0000
1:182939459:ATAC:A	donor_loss	1.0000
1:182939460:TAC:T	donor_loss	1.0000
1:182939461:ACTT:A	donor_loss	1.0000
1:182939462:CT:C	donor_loss	1.0000
1:182939463:T:TC	donor_loss	1.0000
1:182939464:T:TG	donor_loss	1.0000
1:182939465:A:AC	donor_gain	1.0000
1:182939465:AC:A	donor_loss	1.0000
1:182939466:C:CA	donor_gain	1.0000
1:182939466:CA:C	donor_gain	1.0000
1:182939466:CAA:C	donor_gain	1.0000
1:182939466:CAAA:C	donor_gain	1.0000
1:182939466:CAAAT:C	donor_gain	1.0000
1:182939552:ACCTA:A	acceptor_loss	1.0000
1:182940323:TAATA:T	donor_loss	1.0000
1:182940325:ATAC:A	donor_loss	1.0000
1:182940326:TA:T	donor_loss	1.0000
1:182940327:ACCTG:A	donor_loss	1.0000
1:182940330:TGACA:T	donor_gain	1.0000
1:182940338:T:TA	donor_gain	1.0000
1:182940371:T:C	donor_gain	1.0000

AlphaMissense

4305 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:182939525:A:G	W267R	0.999
1:182939525:A:T	W267R	0.999
1:182939243:A:G	W337R	0.998
1:182939243:A:T	W337R	0.998
1:182939302:A:G	L317P	0.998
1:182939475:T:A	R283S	0.998
1:182939475:T:G	R283S	0.998
1:182939476:C:G	R283T	0.998
1:182939529:T:A	R265S	0.998
1:182939529:T:G	R265S	0.998
1:182939530:C:G	R265T	0.998
1:182903132:G:C	S539R	0.997
1:182903132:G:T	S539R	0.997
1:182903134:T:G	S539R	0.997
1:182939203:A:G	L350P	0.997
1:182939476:C:A	R283I	0.997
1:182939523:C:A	W267C	0.997
1:182939523:C:G	W267C	0.997
1:182951322:A:T	V184D	0.997
1:182951392:A:G	W161R	0.997
1:182951392:A:T	W161R	0.997
1:182903151:A:T	V533D	0.996
1:182904198:A:C	S523R	0.996
1:182904198:A:T	S523R	0.996
1:182904200:T:G	S523R	0.996
1:182904232:A:T	V512D	0.996
1:182939195:A:G	W353R	0.996
1:182939195:A:T	W353R	0.996
1:182939522:C:G	D268H	0.996
1:182951404:A:G	W157R	0.996

dbSNP variants (sampled 300 via entrez): RS1000249692 (1:182933978 G>A), RS1000259659 (1:182930578 T>C), RS1000310805 (1:182914950 A>C), RS1000399429 (1:182940330 T>C,G), RS1000410769 (1:182939962 A>C), RS1000530020 (1:182919880 G>A), RS1000604470 (1:182929917 A>G), RS1000757469 (1:182926672 T>C), RS1000778738 (1:182945084 C>T), RS1000782957 (1:182903087 G>A,C), RS1000831748 (1:182953768 A>G), RS1000895117 (1:182922421 G>A), RS1000906225 (1:182951683 G>A), RS1000920197 (1:182903418 A>G,T), RS1000921414 (1:182900330 T>C,G)

Disease associations

OMIM: gene MIM:619514 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST007565_117	Morning person	2.000000e-24
GCST011741_66	LDL cholesterol levels in HIV infection	4.000000e-06

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0008328	chronotype measurement
EFO:0004611	low density lipoprotein cholesterol measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

3 total (human), top 3 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation	1
Estradiol	increases expression	1
Methotrexate	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer